Allogene Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. Unlike autologous CAR T-cell therapies, which are manufactured from a patient's own cells, Allogene's platform focuses on "off-the-shelf" chimeric antigen receptor (CAR) T-cell candidates derived from healthy donors. This approach is designed to deliver cell therapies faster, more reliably, and at a greater scale. The company's lead clinical pipeline includes cemacabtagene ansegedleucel (cema-cel), targeting CD19 for large B-cell lymphoma (LBCL); ALLO-316, targeting CD70 for renal cell carcinoma (RCC); and ALLO-329, a dual-targeting CD19/CD70 candidate for autoimmune diseases.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the pivotal Phase 2 ALPHA3 trial of cema-cel in first-line consolidation large B-cell lymphoma (LBCL) to international territories, including South Korea and Australia, with patient screening and enrollment beginning in Q2 2026.
Expected impact: Accelerates global clinical development and supports potential regulatory submissions outside the United States.
Advancing the Phase 1 RESOLUTION trial of ALLO-329, a dual CD19/CD70 AlloCAR T product candidate leveraging the proprietary Dagger technology designed to reduce or eliminate the need for conventional chemotherapy lymphodepletion.
Expected impact: Aims to establish a highly scalable, tolerable, and accessible off-the-shelf CAR T therapy for autoimmune diseases like systemic lupus erythematosus.
Reclaiming full global development and commercialization rights to four allogeneic CAR T programs (ALLO-715, ALLO-316, ALLO-605, and ALLO-819) by mutually terminating the regional licensing agreement with Overland Therapeutics.
Expected impact: Streamlines the company's portfolio and consolidates global rights, allowing Allogene to independently direct development or pursue alternative global partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Co-develops Foresight's ultra-sensitive minimal residual disease (MRD) assay as a companion diagnostic to identify LBCL patients for treatment with cema-cel in the pivotal ALPHA3 trial.
Terms: Allogene committed to invest approximately $37.3 million for MRD assay development, clinical sample testing, and milestone payments for U.S. and international regulatory submissions.